摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(3-amino-2-methylphenyl)-3-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-1-methylpyrazin-2(1h)-one | 1133433-97-2

中文名称
——
中文别名
——
英文名称
5-(3-amino-2-methylphenyl)-3-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-1-methylpyrazin-2(1h)-one
英文别名
5-(3-amino-2-methylphenyl)-3-[4-(1,4-dimethyl-3-oxopiperazin-2-yl)anilino]-1-methylpyrazin-2-one
5-(3-amino-2-methylphenyl)-3-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-1-methylpyrazin-2(1h)-one化学式
CAS
1133433-97-2
化学式
C24H28N6O2
mdl
——
分子量
432.525
InChiKey
JZADLEPITNIZQD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    32
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    94.3
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Certain Substituted Amides, Method of Making, and Method of Use Thereof
    申请人:Blomgren Peter A.
    公开号:US20110059944A1
    公开(公告)日:2011-03-10
    Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
    本文描述了抑制Btk的化合物I的配方。本文还描述了包括至少一种化合物I的制药组合物,以及至少一种从载体、佐剂和赋形剂中选择的药用可接受载体。本文还描述了治疗对抑制Btk活性和/或B细胞活性敏感的某些疾病的患者的方法。本文还描述了检测样品中Btk存在的方法。
  • Certain substituted pyrazinones
    申请人:CGI Pharmaceuticals, Inc.
    公开号:US07884108B2
    公开(公告)日:2011-02-08
    Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/ or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
    本文描述了一些化学式为I的化合物,它们可以抑制Btk。还描述了包含至少一种化合物I的药物组合物,以及至少一种从载体、佐剂和赋形剂中选择的药用接受者。本文还描述了治疗某些对抑制Btk活性和/或B细胞活性敏感的疾病的患者的方法。还描述了一种确定样品中Btk存在的方法。
  • Certain substituted amides, method of making, and method of use thereof
    申请人:Gilead Connecticut, Inc.
    公开号:US08247550B2
    公开(公告)日:2012-08-21
    Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
    本文描述了化学式I的化合物,其具有抑制Btk的作用。本文还描述了包含至少一种化学式I化合物的制药组合物,以及至少一种从载体、佐剂和赋形剂中选择的药用可接受载体。本文还描述了治疗对Btk活性和/或B细胞活性抑制有响应的某些疾病的患者的方法。本文还描述了检测样品中Btk存在的方法。
  • SUBSTITUTED AMIDES, METHODS OF MAKING, USE THEREOF FOR THE TREATMENT OF DISEASES SUCH AS CANCER
    申请人:Gilead Connecticut, Inc.
    公开号:EP2188267B1
    公开(公告)日:2016-08-03
  • SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS
    申请人:Gilead Connecticut, Inc.
    公开号:EP2297105B1
    公开(公告)日:2015-09-02
查看更多